AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$LLY

Truist raises Eli Lilly stock price target on obesity growth outlook

Truist Securities raised its price target for Eli Lilly (LLY) to $1,612 from $1,376, citing strong growth in obesity and diabetes markets. LLY shares are near a 52-week high, and the company recently reported Q3 2026 earnings of $7.48 per share on $24.4B revenue, beating estimates. Truist maintains a Buy rating, highlighting Lilly's market penetration and pipeline products.

Original reporting
investing.com
Published Oct 30, 2026, 8:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The upgrade and higher price target reflect confidence in Lilly's obesity and diabetes franchise, likely prompting buying interest.

02

Market read

Eli Lilly's strong earnings and upgraded target could drive health‑care sector gains and influence investor sentiment on obesity‑treatment stocks.

03

What to watch

Potential regulatory hurdles for pipeline candidates could temper growth expectations.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Truist Securities upgraded Eli Lilly after reporting Q3 2026 earnings that beat expectations and raised full‑year guidance.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Truist raised its price target on Eli Lilly to $1,612, citing strong Q3 2026 earnings, obesity market penetration and pipeline progress.

Expected impact

likely upward pressure as investors price in stronger guidance and higher target.

Evidence & confidence

The price‑target increase follows a 64% YTD return and better‑than‑expected Q3 results, indicating fresh buying impetus.

Market effects

Sector

Strengthens the broader pharma/biotech outlook, especially obesity‑treatment segment.

Regional

U.S. market may see modest rally in health‑care stocks.

Global

Highlights growing demand for obesity drugs worldwide, could influence global biotech valuations.

Counterpoint

What could challenge this read

If obesity drug competition intensifies, the target may be overly optimistic.

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical company with ticker LLY.

  • analyst
    Truist Securities

    Research firm that raised the price target.

Read at source← All news

Related articles

OCT 30
$LLYMed

BMO raises Eli Lilly stock price target on metabolic strength

BMO Capital raised its price target for Eli Lilly (NYSE:LLY) to $1,650, citing strong metabolic disease franchise performance and recent guidance increases. The stock, trading at $1,373.70, has surged 64% over the past year. Eli Lilly's revenue grew 46% to $86.5 billion, with an 84% gross profit margin. The company's Q3 2026 earnings of $7.48 per share beat expectations, with revenue of $24.4 billion. Several analysts raised their price targets following the strong results.

investing.com2 min
OCT 30
$LLYMedAI 9/10

Retatrutide Tops Ozempic for Weight Loss, A1c in T2D

Eli Lilly's retatrutide showed superior weight loss and A1c reduction in type 2 diabetes patients compared to Ozempic in a phase 3 trial, with participants losing 44.3-47.4 lbs vs 20.9 lbs. Retatrutide also improved cardiovascular risk factors. Lilly warns against illegal online sales of the unapproved drug.

medscape.com2 min
OCT 30
$LLYHigh

Lilly reports retatrutide advantage over Ozempic in diabetes trial

Eli Lilly reported that retatrutide showed greater A1C and weight reduction than Ozempic in a type 2 diabetes trial. The study involved 1,298 adults, with retatrutide doses of 9 mg and 12 mg compared to Ozempic's 2 mg over 80 weeks. Lilly noted average A1C reductions of 2.2 points for retatrutide versus 1.8 for Ozempic, and weight reductions of 19.5% and 20.9% versus 9.4%. Safety concerns were highlighted, with higher discontinuation rates for retatrutide due to adverse events.

paktribune.com2 min
OCT 29
$GOOGLMedAI 8/10

Alphabet's AI Spending Shock Drags Nasdaq Down 1.7% as Wall Street's Big Three Retreat

Alphabet's shares fell 13.2% after its quarterly report missed revenue forecasts and showed increased AI spending, dragging the Nasdaq down 1.7%. The S&P 500 and Dow Jones also declined. Investors are differentiating between companies funding AI internally and those relying on debt or cash burn. Other notable movers include Caterpillar (-9.5%), Fortinet (-20%), and Eli Lilly (+6.3%).

finance.biggo.com6 min
OCT 29
$LLYHighAI 9/10

Lilly Raises 2026 Revenue Outlook as Mounjaro, Zepbound Sales Rise

Eli Lilly raised its 2026 revenue outlook to $91B-$92B due to strong sales of Mounjaro and Zepbound, reporting Q3 revenue of $24.4B, up 38% YoY. Mounjaro revenue grew 65% to $10.7B, while Zepbound grew 49% to $5.35B. Non-GAAP EPS was $7.48, up 7% YoY. Lilly cited acquisition-related charges for a slight EPS forecast reduction.

econotimes.com5 min